Reversal of medication abortion with progesterone: a systematic review

Bianca Maria Stifani, Antonella Francheska Lavelanet

ABSTRACT

INTRODUCTION

Medication abortion accounts for an increasing proportion of abortions. Medication management using mifepristone followed by misoprostol is highly effective and safe. Most individuals who have medication abortions are highly satisfied with their experience, as individuals are often sure of their decision and feel relief rather than regret after the abortion. Rarely, some pregnant individuals who take mifepristone to terminate a pregnancy choose not to complete the abortion process.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ A 2015 systematic review of progesterone to reverse the effects of mifepristone found one study that met inclusion criteria and concluded that there is insufficient evidence to recommend this treatment. Since then, new studies have been published and more practitioners around the world have started offering progesterone to individuals no longer wishing to complete a medication abortion after taking mifepristone.

WHAT THIS STUDY ADDS

⇒ We undertook a review of the three new studies published on this topic and conclude that there remains insufficient evidence to recommend progesterone for individuals no longer wishing to complete the medication abortion process. Further, one of the new studies was halted due to bleeding events, highlighting safety concerns with not taking misoprostol after mifepristone.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Practitioners should be aware that there is insufficient evidence to recommend progesterone treatment to reverse the effects of mifepristone, and potential risk to not taking misoprostol after mifepristone. Any further studies on this topic should be conducted in a controlled setting given the potential safety risks.
Mifepristone is a progesterone receptor antagonist that blocks the progesterone receptor with a higher affinity than progesterone itself, and it has a half-life of 25–30 hours. A 200 mg dose of mifepristone is undetectable in humans 10 days after ingestion. It disrupts pregnancy by promoting decidual necrosis; it also softens the cervix and increases uterine contractility and sensitivity to prostaglandins. Some have hypothesised that when individuals no longer desire abortion after ingestion of mifepristone, administering high doses of progesterone increases the rates of ongoing pregnancy compared with expectant management. However, it is unclear whether progesterone can counteract the effects of mifepristone. Data show that high-dose prostogestogens can decrease the efficacy of medication abortion. In a randomised trial, the ongoing pregnancy rate after medication abortion was 3.6% in the group that received depot medroxyprogesterone acetate at the same time as mifepristone, compared with 0.9% in the group that received it at a later time. Administration of lower doses such as those delivered by the etonogestrel implant, on the other hand, do not seem to impact medication abortion success rates.

Several states in the United States require that medication abortion users be informed about the potential of reversing the effects of mifepristone should they change their mind about the abortion. Further, some groups that advocate for decreased access to abortion advertise “abortion pill reversal” on the internet. Recently, these groups have gained traction globally, partnering with local activists and practitioners in Europe, Latin America and elsewhere to provide what they promote as “abortion reversal” regimens. However, this practice is not included in any national or international guideline on medication abortion.

The American College of Obstetricians and Gynecologists states that “[c]laims regarding abortion ‘reversal’ treatment are not based on science and do not meet clinical standards”. The Royal College of Obstetricians and Gynaecologists along with other professional organisations in the UK issued a similar statement in 2022.

The authors of a 2015 systematic review on the reversal of medication abortion using progesterone found only one study that met inclusion criteria for review. They also reviewed the existing literature on ongoing pregnancy rates among individuals who took mifepristone alone in trials of medication abortion and reported rates ranging from 8% to 46% with different mifepristone regimens. The authors concluded that there was insufficient evidence to recommend progesterone treatment to reverse the effects of mifepristone. Since then, new studies have been published on this topic, and discussion, as well as promotion, of abortion reversal is increasing in certain parts of the world.

We therefore undertook an updated systematic review of the literature around use of progesterone after mifepristone. The objective of this review is to determine whether there is new sufficient evidence to recommend treatment with progesterone for pregnant individuals who took mifepristone and no longer wish to complete the medication abortion process.

METHODS

Search strategy

We conducted two systematic searches: one for studies of abortion reversal with progesterone (main search), and another for studies documenting ongoing pregnancy rates after mifepristone alone (secondary search). We performed the searches in December 2021, then again in December 2022. For the main search, we searched PubMed, Embase, Cochrane and CINAHL. We also searched Google Scholar and GreyLit.org for grey literature sources and searched the reference lists of existing publications. With the help of a librarian, we built search constructs appropriate for each database. We uploaded all citations to Mendeley and then to Covidence, where we removed all duplicates. The two researchers performed title and abstract screening of all studies and full-text screening of studies that initially appeared to meet eligibility criteria. We resolved any conflicts via discussion. We report our methods and findings in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Of note, we recognise that the term “antagonisation” would be more scientifically accurate than “reversal” since the perceived action of progesterone would be at the receptor level. However, we chose to use the term “reversal” for simplicity because it has been most often used both in the scientific literature and by individuals who promote this practice.

For the secondary search, we focused on studies that reported continuing pregnancy rates after use of mifepristone alone, as the authors of the 2015 systematic review had done. We searched PubMed using the same search strategy as mentioned earlier without the reversal term. We only searched for studies published after March 2015, as those published earlier were included in the previous systematic review.

Study selection

For the main search, we included studies in which pregnant individuals took mifepristone to induce abortion but did not take misoprostol, and in which at least one study arm received progesterone, or any other pharmacological intervention administered in any dosage or form for the purpose of reversing the effects of mifepristone. Because we anticipated few if any randomised trials, we included all types of primary studies with and without comparison groups, even case series. We defined case series as “a group or series of case reports involving patients who were given similar treatment”. Included studies had to report...
on our primary outcome, which was the proportion of participants with ongoing pregnancy after treatment with progesterone or any other pharmacological intervention for abortion reversal. The secondary outcomes were treatment side effects or complications, and the incidence of birth defects. We included any listed complications or side effects including bleeding, surgical intervention and gastrointestinal side effects. We included studies even if they did not include any of our predetermined secondary outcomes. We excluded review articles, editorials, letters, advisories, unpublished manuscripts and commentaries.

For the secondary search, we included cohort studies and randomised controlled trials in which pregnant individuals took mifepristone; did not take misoprostol; and did not receive progesterone or any other pharmacological intervention to reverse the effects of mifepristone. The primary and secondary outcomes were the same as those for the primary search.

Study synthesis and assessment
The two authors extracted data on the predefined primary outcome, reporting on the number of participants enrolled in each study or included in each case series, and the number of continuing pregnancies. We also extracted data on the secondary outcomes for the studies which reported on them. For the primary analysis we calculated the overall proportion (and 95% Wilson Score Confidence Interval, CI) of ongoing pregnancies following treatment with progesterone, compared with the overall proportion (and 95% Wilson Score CI) of ongoing pregnancies following mifepristone alone. For this analysis, we included studies in which participants had received 200 mg mifepristone in the mifepristone alone group, as that is the regimen currently used in clinical practice.2.3 In this group, we considered data from studies that were published prior to 2015 and included in the 2015 systematic review but were not part of the results of our secondary search beginning in March of 2015. We also analysed data according to gestational age as it is a main predictor of ongoing pregnancy after mifepristone use.

The two researchers independently conducted a critical appraisal for each study, then met to discuss results and resolve conflicts. For the case series, we used the Case Series Critical Appraisal Tool developed by the Joanna Briggs Institute (JBI).26 For the randomised controlled trial, we used the JBI Checklist for Randomised Controlled Trials.27 We chose the JBI institute tools because they are the only ones we are aware of that include a tool for case studies.

RESULTS
Characteristics of included studies
For the main search, we identified 1284 references through database and grey literature searches. We removed 337 duplicates and screened 947 references. Of these, we excluded 932 irrelevant references based on title and abstract screening and selected 15 for full-text screening. We excluded 11, which were the wrong study design (primarily commentaries) and included a total of four studies in the review (see figure 1, PRISMA flow diagram). In the secondary search, we screened 443 references and did not find any new studies that reported on continuing pregnancies after use of mifepristone alone.

We included four studies from our main search in this review. Three studies were case series and did not have comparison groups.28-30 Of these, only one had been included in the 2015 systematic review of abortion reversal.21 28 The fourth study is a double-blind, randomised, placebo-controlled trial.31 Table 1 shows the characteristics of the included studies.

The first study was a case series of seven patients who took mifepristone for medication abortion and then changed their mind and attempted reversal with progesterone.28 Their gestational ages ranged from 7 to 11 weeks and the treatment with progesterone was started at 7–72 hours after mifepristone ingestion. Progesterone regimens varied (see table 2 for details). Timing of progesterone initiation also varied. Although the article included few details, it appears that gestational cardiac activity was documented on ultrasound prior to initiating progesterone in at least five of the cases. Pregnancy outcomes were available for six of the seven patients and were assessed via patient history. One patient was lost to follow-up. The study did not report on any of our predetermined secondary outcomes.

The second study was a case series of three patients selected among women who contacted an Australian pregnancy support service via the internet and who received a 2-week vaginal progesterone course for abortion reversal.30 Timing of progesterone initiation varied. Pregnancy outcomes were assessed via ultrasound at varying timepoints and/or patient history. The study did not report on any of our predetermined secondary outcomes.

The third study was a larger case series of patients selected among women from “several different countries” who called a hotline for abortion reversal.29 A total of 325 different healthcare providers treated them with various progesterone regimens. The maximum interval between mifepristone and initiation of progesterone was 72 hours. A total of 1668 women called the hotline expressing interest in progesterone, but only 754 initiated progesterone therapy. It is unclear why the remaining 954 did not initiate therapy. The authors excluded an additional 207/754 women from the analysis because they later chose to complete the abortion, were >72 hours after taking mifepristone, or were lost to follow-up. Pregnancy outcomes were available for 547 women and were assessed via patient history. It appears that gestational cardiac activity was documented prior to initiation of progesterone treatment in some cases and not others. The study did not report on
any of our predetermined secondary outcomes, other than the incidence of birth defects.

Of note, we strongly considered excluding this publication from the primary review because it does not contain detailed follow-up information for all patients. However, we chose to include it because the guidelines for case series are not well established. According to the National Cancer Institute, “reports of case series usually contain detailed information about the individual patients, (including) demographic information (for example, age, gender, ethnic origin) and information on diagnosis, treatment, response to treatment, and follow-up after treatment”. However, case series are not mentioned in the STROBE guidelines for observational studies, so there are no clear elements that must be reported for a study to qualify as a case series. As some epidemiologists have noted, “a case series can be incomplete; completeness would contribute to the reliability of the study, but the study remains a case series even if it is incomplete.”

None of the case series included here specify the dose of mifepristone individuals ingested, but 200 mg was the dose recommended by international guidelines at the time the studies were conducted.

The fourth study was a randomised, double-blind, placebo-controlled trial in which individuals at 44–63 days of pregnancy who were awaiting surgical abortions agreed to take mifepristone and were randomised to receiving high-dose oral progesterone or placebo 24 hours after mifepristone ingestion. The primary outcome was continued gestational cardiac activity at 2 weeks as determined via ultrasound. This was the only study which also reported on our predetermined secondary outcomes of treatment side effects and complications. It is important to note that although researchers planned to include 20 patients in each arm, enrollment stopped early due to bleeding events in both arms.

**Synthesis of results**

The four selected studies included a total of 561 individuals who received progesterone treatment after taking mifepristone, and for whom the primary outcome of ongoing pregnancy could be assessed. Of these, a total of 271 (48%) had ongoing pregnancies. Only one study had a control group, and 2/6 patients in that group had ongoing pregnancies. The same study was also the only one to report on treatment side effects.

---

**Figure 1** Summary of study selection process for inclusion in the systematic review of ongoing pregnancies after mifepristone and either treatment with progesterone (main search) or expectant management (secondary search).
Table 1  Characteristics of studies included in a systematic review of abortion reversal

<table>
<thead>
<tr>
<th>Authors (year)</th>
<th>Study type</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparison</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delgado &amp; Davenport (2012)</td>
<td>Case series</td>
<td>US women who took mifepristone for abortion and were interested in reversing effect; pelvic ultrasound performed prior to initiating treatment in at least 5/7; mifepristone dose unspecified</td>
<td>Treatment with progesterone (various regimens)*</td>
<td>None</td>
<td>Proportion of ongoing pregnancies -- assessed via patient history (timing of assessment not specified) tSecondary outcomes: none</td>
</tr>
<tr>
<td>Garratt &amp; Turner (2017)</td>
<td>Case series</td>
<td>Women in Australia who took mifepristone and were interested in reversing effect; pelvic ultrasound not performed prior to initiating treatment; mifepristone dose unspecified</td>
<td>Vaginal progesterone for 2 weeks: None 400 mg twice daily for 3 days, then 400 mg nightly for 6 days, then 200 mg nightly for 6 days</td>
<td>None</td>
<td>Proportion of ongoing pregnancies -- assessed via ultrasound and patient history (timing of assessment varied) tSecondary outcomes: none</td>
</tr>
<tr>
<td>Delgado et al (2018)</td>
<td>Case series</td>
<td>Pregnant women in US and several other countries who had taken mifepristone but not misoprostol and were interested in reversing effects; 72 hours or less after taking mifepristone; mifepristone dose unspecified</td>
<td>Various progesterone dosing/formulations: high-dose oral, intramuscular (various doses and frequencies), oral caps, vaginal suppository</td>
<td>None</td>
<td>Proportion of ongoing pregnancies -- assessed via patient history (timing of assessment not specified) tSecondary outcomes: incidence of birth defects</td>
</tr>
<tr>
<td>Creinin et al (2020)</td>
<td>Double-blind, randomised, placebo-controlled trial</td>
<td>Patients at 44–62 days of gestation with confirmed cardiac activity who were planning surgical abortion</td>
<td>Mifepristone 200 mg, followed 24 hours later by oral progesterone 400 mg - twice daily for 3 days, then once daily until planned surgical abortion 14–16 days after enrollment</td>
<td>Mifepristone 200 mg followed by placebo</td>
<td>Proportion of ongoing pregnancies at 2 weeks -- assessed via ultrasonography tSecondary outcomes: complications and side effects</td>
</tr>
</tbody>
</table>

*See individual cases in table 2 for details on treatment regimens.
†Secondary outcomes: our secondary outcomes of interest were treatment side effects and complications (including bleeding, surgical intervention and gastrointestinal side effects) and birth defects.

and complications. Of the 12 patients included in that study (six in the treatment arm and six in the control arm), five patients experienced complications (two in the treatment arm and three in the placebo arm). Table 2 shows the primary and secondary outcomes for all included studies.

The larger case series reported ongoing pregnancy rates according to gestational age at which mifepristone was ingested. They were 25% at 5 weeks, 46% at 6 weeks, 49% at 7 weeks, 61% at 8 weeks and 77% at 9 weeks (table 2).

Pooled analysis of ongoing pregnancy rates

For the planned analysis of ongoing pregnancy rates, we included data from two studies in the mifepristone alone group: data from the control group of the 2020 Creinin et al study, and data from a 1988 study by Maria et al. We included data from the Maria et al study (which was also included in the 2015 systematic review) because it is the only study of mifepristone alone in which participants received 200 mg of mifepristone. Because this study only included participants who were 7 weeks pregnant or less, we applied the same criterion to the progesterone group and excluded from this analysis participants who were more than 7 weeks pregnant at the time of mifepristone ingestion.

We also compared ongoing pregnancy rates for pregnancies of 7–8 weeks by comparing those treated with progesterone to the control group of the Creinin et al study only. Table 3 shows the ongoing pregnancy rate for all pregnancies 7 weeks or less in the four included studies, which was 42% (95% CI 37 to 48). In comparison, the ongoing pregnancy rate at 7 weeks or less after mifepristone alone based on the Maria et al study and the Creinin et al study’s control group was 22% (95% CI 11 to 39). For pregnancies of 7–8 weeks, the ongoing pregnancy rate after progesterone treatment was 62% (95% CI 52 to 71) compared with 50% (15–85%) in the Creinin et al control group.

Quality of the evidence

For the three case series we rated the quality of the evidence as low, but we chose to include them in this review as there is very limited evidence available on this topic. online supplemental table 1 shows our critical appraisal of these studies, and online supplemental table 2 shows a detailed explanation of our ratings. For two of the studies it was unclear how many individuals had presented seeking medication abortion reversal, whether any of those who had presented were not offered progesterone, and whether all of the women treated with progesterone were included in the case series. For the two case series published by Delgado and colleagues it was unclear whether the pregnancy outcomes were assessed in a standardised way (eg, ultrasound vs chart review vs patient report). Also, some but not all participants had
## Table 2  Characteristics and pregnancy outcomes of individuals treated with progesterone or placebo for abortion reversal in the four studies included in this review

<table>
<thead>
<tr>
<th>Case</th>
<th>GA (days or weeks)</th>
<th>Treatment initiation time</th>
<th>Regimen</th>
<th>Outcomes (pregnancy outcome, complications or side effects)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delgado &amp; Davenport(^{28}) (2012)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>8 weeks</td>
<td>30–40 hours</td>
<td>200 mg in oil, IM, daily x 2 days; then two doses every other day x 2; then twice weekly until 9 weeks 5 days; then restarted at 11 weeks 2 days, twice weekly; then decreased to 100 mg twice weekly until 29 weeks 5 days</td>
<td>Viable infant at 37 weeks</td>
</tr>
<tr>
<td>2</td>
<td>11 weeks</td>
<td>72 hours</td>
<td>200 mg in oil, IM; continued for 2 weeks (unknown frequency); then PO micronised progesterone for 5 months (unknown frequency and dosage)</td>
<td>Viable infant</td>
</tr>
<tr>
<td>3</td>
<td>7 weeks</td>
<td>36–48 hours</td>
<td>200 mg in oil, IM; then two more times the first week, then weekly for 5–6 weeks, then 200 mg in oil twice weekly for 2 weeks, then micronised progesterone orally for 5 months</td>
<td>Viable infant at 39 weeks</td>
</tr>
<tr>
<td>4</td>
<td>7 weeks 4 days</td>
<td>46 hours</td>
<td>200 mg in oil, IM, twice weekly for 19 weeks</td>
<td>Viable infant at 40 weeks</td>
</tr>
<tr>
<td>5</td>
<td>Unknown</td>
<td>Unknown</td>
<td>200 mg in oil, route and frequency unknown</td>
<td>Abortion soon after injection</td>
</tr>
<tr>
<td>6</td>
<td>7 weeks</td>
<td>7 hours</td>
<td>200 mg PV; followed by IM 200 mg after 11 hours; then 2 days later</td>
<td>Abortion complete 3 days after mifepristone</td>
</tr>
<tr>
<td>7</td>
<td>Lost to follow-up; no information available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garratt &amp; Turner(^{30}) (2017)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>43 days</td>
<td>28 hours</td>
<td>Vaginal progesterone: 400 mg twice daily for 3 days, then 400 mg nightly for 6 days, then 200 mg nightly for 6 days; routine antenatal care after 2 weeks of progesterone</td>
<td>Viable pregnancy at 8 weeks 4 days on ultrasound at 2 weeks; viable infant at 39 weeks</td>
</tr>
<tr>
<td>T</td>
<td>61 days</td>
<td>3.5 hours</td>
<td>Same as above</td>
<td>LTFU at 2-week follow-up ultrasound; reported delivery of live infant &quot;7 months later, likely at term&quot;</td>
</tr>
<tr>
<td>O</td>
<td>7.5 weeks</td>
<td>31 hours</td>
<td>One dose of vaginal progesterone 400 mg; discontinued as experienced heavy vaginal bleeding soon after treatment initiation</td>
<td>Heavy vaginal bleeding soon after starting progesterone; follow-up US at 1 week showed empty uterus, completed abortion</td>
</tr>
<tr>
<td>Delgado et al(^{29})</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>754 treated</td>
<td>Variable (72 hours or less)</td>
<td>High-dose oral progesterone: 31 IM progesterone: 125 Vaginal caps: 156 Vaginal suppository: 34 Unknown: 82</td>
<td>Outcomes available for 547: Births: 257 LTFU before 20 weeks: 112 LTFU after 20 weeks: 4 Excluded because chose to complete abortion: 57 Excluded because wrong time interval: 38 Ongoing pregnancies by progesterone regimen: High-dose oral: 21/31 (68%) IM progesterone all groups: 80/125 (64%) Oral, all groups: 64/119 (54%) Vaginal caps: 61/156 (39%) Vaginal suppository: 11/34 (32%) Ongoing pregnancies by gestational age: 5 weeks: 19/76 (25%) 6 weeks: 61/113 (46%) 7 weeks: 50/102 (49%) 8 weeks: 54/88 (61%) 9 weeks: 23/30 (77%) Birth defects: 6 (2 absent digits; 1 choroid plexus cyst, 1 cystic kidney, 1 failed hearing test, 1 heart murmur)</td>
</tr>
<tr>
<td>Creinin et al(^{31}) (2020)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>53 days</td>
<td>24 hours</td>
<td>Mifepristone 200 mg, followed by oral progesterone 400 mg 24 hours later - twice daily for 3 days, then once daily until planned surgical abortion 14–16 days after enrollment</td>
<td>Continuing GCA at 17 days</td>
</tr>
<tr>
<td>2</td>
<td>50 days</td>
<td>24 hours</td>
<td>Same as above</td>
<td>Continuing GCA at 16 days</td>
</tr>
<tr>
<td>5</td>
<td>49 days</td>
<td>24 hours</td>
<td>Same as above</td>
<td>Continuing GCA at 16 days</td>
</tr>
<tr>
<td>8</td>
<td>56 days</td>
<td>24 hours</td>
<td>Same as above</td>
<td>Expelled pregnancy, haemorrhage not requiring transfusion or uterine aspiration at day 3</td>
</tr>
</tbody>
</table>

Continued
ultrasounds to confirm gestational cardiac activity prior to initiating progesterone, and there were no stated criteria for ultrasound use.\(^28\)\(^29\) For the 2018 Delgado et al case series less than one-third (547/1668) of the women who initially expressed interest in progesterone treatment were included in the analysis. While the reasons for exclusion are clear for 207 of these women, they are not for the remaining 914 women. It is possible that some of the latter women may have been excluded because of embryonic demise at the time of presentation, or because they were experiencing bleeding or pain. For the Creinin study we rated the quality of the evidence as high given the randomised, double-blind study design (online supplemental table 3). However, the study did not reach the intended sample size as researchers stopped enrollment early due to safety concerns.

**DISCUSSION**

Our review of the use of progesterone to reverse the effect of mifepristone found that ongoing pregnancy rates are not significantly different for individuals treated with progesterone compared with those managed expectantly. Also, individuals who do not receive misoprostol after mifepristone may be at increased risk of bleeding.

We found few studies investigating the effect of progesterone treatment to reverse the effects of mifepristone. Only one study was rigorously designed but did not reach its intended sample size due to safety concerns. The remainder were case series with serious ethical and methodological concerns. We compared the ongoing pregnancy rate at 7 weeks or less and 7–8 weeks for individuals treated with progesterone after mifepristone compared with those who were managed expectantly, pooling data from the four studies in

<table>
<thead>
<tr>
<th>Case</th>
<th>GA (days or weeks)</th>
<th>Treatment initiation time</th>
<th>Regimen</th>
<th>Outcomes (pregnancy outcome, complications or side effects)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>47 days</td>
<td>24 hours</td>
<td>Same as above</td>
<td>Nausea, vomiting, dehydration; requested aspiration at day 3</td>
</tr>
<tr>
<td>12</td>
<td>48 days</td>
<td>24 hours</td>
<td>Same as above</td>
<td>Continuing GCA at 15 days</td>
</tr>
<tr>
<td>3</td>
<td>50 days</td>
<td>24 hours</td>
<td>Placebo</td>
<td>Continuing GCA at 16 days</td>
</tr>
<tr>
<td>4</td>
<td>48 days</td>
<td>24 hours</td>
<td>Placebo</td>
<td>No GCA at 4 days</td>
</tr>
<tr>
<td>6</td>
<td>61 days</td>
<td>24 hours</td>
<td>Placebo</td>
<td>Continuing GCA at 16 days</td>
</tr>
<tr>
<td>7</td>
<td>48 days</td>
<td>24 hours</td>
<td>Placebo</td>
<td>D&amp;C requested (bleeding, anxiety) at day 4</td>
</tr>
<tr>
<td>10</td>
<td>60 days</td>
<td>24 hours</td>
<td>Placebo</td>
<td>Expelled pregnancy, incomplete, emergent D&amp;C at day 5</td>
</tr>
<tr>
<td>11</td>
<td>60 days</td>
<td>24 hours</td>
<td>Placebo</td>
<td>Expelled pregnancy, incomplete, emergent D&amp;C, transfusion at day 6</td>
</tr>
</tbody>
</table>

*Unclear if this group includes the individuals treated with high-dose oral progesterone.

D&C, dilation and curettage; GA, gestational age; GCA, gestational cardiac activity; IM, intramuscular; LTFU, lost to follow-up; N/A, not available; PO, per os; PV, per vagina; US, ultrasound.

**Table 2** Continued

<table>
<thead>
<tr>
<th>Case</th>
<th>GA (days or weeks)</th>
<th>Treatment initiation time</th>
<th>Regimen</th>
<th>Outcomes (pregnancy outcome, complications or side effects)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>61 days</td>
<td>24 hours</td>
<td>Placebo</td>
<td>Continuing GCA at 16 days</td>
</tr>
<tr>
<td>7</td>
<td>48 days</td>
<td>24 hours</td>
<td>Placebo</td>
<td>D&amp;C requested (bleeding, anxiety) at day 4</td>
</tr>
<tr>
<td>10</td>
<td>60 days</td>
<td>24 hours</td>
<td>Placebo</td>
<td>Expelled pregnancy, incomplete, emergent D&amp;C at day 5</td>
</tr>
<tr>
<td>11</td>
<td>60 days</td>
<td>24 hours</td>
<td>Placebo</td>
<td>Expelled pregnancy, incomplete, emergent D&amp;C, transfusion at day 6</td>
</tr>
</tbody>
</table>

**Table 3** Proportion of pregnant individuals with continuing pregnancies after taking mifepristone at 7 weeks’ gestation or less, and at 7–8 weeks’ gestation, with or without progesterone

<table>
<thead>
<tr>
<th>Authors (year)</th>
<th>7 weeks of pregnancy or less</th>
<th>7–8 weeks of pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total pregnancies (n)</td>
<td>Ongoing pregnancies (n)</td>
</tr>
<tr>
<td>Mifepristone 200 mg + progesterone (any dose)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delgado &amp; Davenport(^28) (2012)</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Garratt &amp; Turner(^26) (2017)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Delgado et al(^29) (2018)</td>
<td>291</td>
<td>121</td>
</tr>
<tr>
<td>Creinin et al(^31) (2020)</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>297</td>
<td>125</td>
</tr>
<tr>
<td>Mifepristone 200 mg alone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maria et al(^35) (1998)*</td>
<td>30</td>
<td>7</td>
</tr>
<tr>
<td>Creinin et al(^31) (2020)</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>32</td>
<td>7</td>
</tr>
</tbody>
</table>

CIs are calculated 95% Wilson Score CIs.

*All participants in this study were at 49 days of gestation or less.
Systematic review

this review and the only prior study which examined ongoing pregnancy rates after a 200 mg dose of mifepristone. Even including all the data from the poorly conducted case series, ongoing pregnancy rates are not significantly higher for individuals treated with progesterone compared with those managed expectantly.

Most of the data in this analysis were collected as part of a large case series with ethical and methodological issues. While we considered excluding it from the analysis, we ultimately included it because it did meet our definition of case series, though its lack of completeness and inclusiveness of cases over time limits its reliability. This case series by Delgado et al reported a success rate of progesterone treatment of up to 68%. As was also highlighted by authors who conducted a partial reanalysis of those findings, this success rate was likely inflated by two factors. While some participants had gestational cardiac activity confirmed by ultrasonography prior to initiating progesterone, it is unclear how many individuals in total had ultrasound examinations and how many were excluded from the study because they already had an embryonic demise prior to initiating progesterone. Only selecting individuals who had gestational cardiac activity at the time they sought abortion reversal would falsely inflate progesterone’s success rate because mifepristone alone does not always cause embryonic demise, particularly at higher gestational ages. Also, the authors excluded from the analysis individuals who were lost to follow-up before 20 weeks, many of whom may have experienced embryonic demise.

Both the 2012 and 2018 case series we included in the review also raise ethical concerns. First, investigators and their associated institutions have a responsibility to ensure that research is conducted ethically. The 2012 case series does not mention obtaining informed consent, nor does it mention institutional review board (IRB) approval or review, which is inappropriate as the authors report giving an experimental treatment and following patients prospectively. In the 2018 case series, in which more than 700 women received an experimental treatment, the authors obtained “written informed consent that included permission to track [the individuals] data” and claim that the study received an “institutional review board waiver”. However, this study was temporarily retracted due to ethical concerns as the authors initially failed to provide information about IRB approvals.

Second, journals and publishers have a role in promoting ethical conduct in research and publishing. The 2018 case series was published in the journal Issues in Law & Medicine. This journal consistently publishes articles written by individuals and funded by sources which openly oppose access to abortion, without disclosing its ties to this movement, potentially biasing the results. While location of publication was not a criterion for inclusion in this review, it is important to raise the possibility that the peer review process in such journals may not have been as transparent as in other scientific journals.

Another limitation of the studies included in this analysis is that only one study reported treatment side effects and complications. The 2018 case series included information about birth defects but nothing about side effects or complications experienced by the women treated with progesterone. In the Creinin et al study, a concerning number of participants experienced complications in both arms of the study. In the six-patient treatment group, one patient had a haemorrhage not requiring a blood transfusion. In the six-patient control group, two had haemorrhages requiring uterine aspiration, one of which also required transfusion. Similar events may have arisen in the other case series but were not reported. These findings suggest that when individuals change their mind after ingesting mifepristone for medication abortion, both expectant management and treatment with progesterone may be associated with a higher risk of bleeding than continuing the abortion with misoprostol, where complications requiring emergency department visits are rare.

In conclusion, based on data from poorly conducted studies that may not have undergone rigorous peer review, there is insufficient evidence to recommend progesterone for individuals who change their minds after initiating the medication abortion process. Only one study included was of high quality, but we cannot draw conclusions related to effectiveness as it was stopped due to safety concerns. Given these concerns, any further studies of this topic should be conducted in a controlled environment, and they should be rigorously designed and ethically conducted.

Ultimately, obtaining high-quality evidence on whether progesterone can reverse the effects of mifepristone could help provide patient-centred care for the small minority of individuals who do change their minds after starting the medication abortion process. The WHO defines people-centred care as an approach to care in which “people have the education and support they need to make decisions and participate in their own care”. Providing accurate information to those who are interested in reversing the effects of mifepristone would be in line with these principles. Similarly, obtaining additional data about the efficacy and safety of these treatment options would enable policymakers to meet their international human rights law obligations to ensure that individuals have access to accurate and evidence-based information to inform their decision-making. However, until such evidence is available, clinicians who seek to support patients in this way should be cautious about providing high-dose progesterone off-label given the lack of evidence of benefit and the potential safety concerns. Clinicians should also counsel patients that expectant management may be less safe than completing the medication abortion process with misoprostol.
Registration
We did not register this review. The review protocol was not published but is available on request.

Acknowledgements
The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) funded this work. The named authors alone are responsible for the views expressed in this publication and do not necessarily represent the decisions or the policies of the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) or the World Health Organization (WHO).

Contributors
AFL had the idea for this systematic review. AFL and BMS designed the systematic review protocol and decided on search strategies. AFL and BMS conducted abstract and full-text screening. BMS extracted data and wrote the first draft of the manuscript. AFL and BMS revised the manuscript and approved the final version. AFL and BMS accept full responsibility as guarantors.

Funding
The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) funded this work.

Competing interests
None declared.

Patient and public involvement
Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Not applicable.

Ethics approval
Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Bianca Maria Stifani http://orcid.org/0000-0001-9740-4703

REFERENCES
20. Royal College of Obstetricians and Gynaecologists (RCOG), Faculty of Sexual and Reproductive Healthcare (FSRH), Royal College of Midwives (RCM). Joint statement on
Abortion reversal: The Royal College of Obstetricians and Gynaecologists (RCOG), the Faculty of Sexual and Reproductive Healthcare (FSRH), the Royal College of Midwives (RCM) and the British Society of Abortion Care Providers (BSACP); 2022. Available: https://www.rcog.org.uk/media/nbahlqvo/rcog-fsrh-abortion-reversal-position-statement.pdf [Accessed 1 Apr 2022].


